News | April 08, 2022
Cadila Pharma launches world’s first three-dose rabies vaccine
The recombinant nanoparticle-based rabies G protein vaccine is prepared using virus-like particle technology.
The recombinant nanoparticle-based rabies G protein vaccine is prepared using virus-like particle technology.
New high-throughput, no-wash assays contribute to the development, manufacture and quality control of safer, more effective biotherapeutics
CanSinoBIO will continue to focus on developing a variety of innovative preventive vaccines in its diversified product pipeline with proprietary technologies, including the inhaled version of its COVID-19 vaccine, Convidecia
Companies to leverage proprietary IgM antibody technology platform to discover agonists against three oncology targets and three immunology/inflammation targets
Data published in the prestigious journal ACS Central Science of the American Chemical Society
Sputnik Light is the first component of Sputnik V
Inconsistent antibody performance is a significant challenge for researchers and sits at the heart of the reproducibility crisis observed in biomedical research
mRNA-based therapies involve the administration of mRNA in patients so that patients' own cells can produce the encoded therapeutic antibody
Jointly fund and develop up to three antibody-drug conjugate programs for the treatment of cancer
Under the agreement, both companies will conduct collaborative research utilizing NuclixBio's proprietary circular mRNA platform named 'ringRNA’ to develop novel mRNA therapeutics that can generate PharmAbcine's antibodies
Subscribe To Our Newsletter & Stay Updated
